← Evidence library

BIB_377

Chronotherapy of immune checkpoint inhibitors (ICI) — time-of-day scheduling affects melanoma and pan-cancer survival. Primary melanoma-specific evidence: MEMOIR (Qian 2021 Lancet Oncol, n=299 stage IV) — ≥20% infusions after 16:30 → OS HR 1.69 (1.03–2.78; P=0.038). Meta-analytic evidence: Landré 2024 ESMO Open (13 studies, n=1,663 including 20% melanoma) — early-vs-late OS HR 0.50 (0.42–0.58; P<0.00001). Phase 3 RCT: LungTIME-C01 (Huang 2025 Nature Med, n=210 NSCLC) — early-vs-late OS HR 0.43 (0.27–0.69; P=0.0003) — ⚠ UNDER EDITORIAL INTEGRITY INVESTIGATION; do not use as standalone evidence.…

Evidence grade

B

Tier

2 (MEMOIR Lancet Oncol 2021 — Tier 1 journal; retrospective propensity-matched,

Cited by tasks

17, 18, 24

Identifiers

PMC10937202 · DOI:10.1016/S1470-2045(21 · PMID:39191524

↗ Follow the original source for full context

Full extracted findings & patient-implication analysis: bibliography/BIB_377/findings.md (research corpus). This page is a short context summary — not individualised medical advice.